# Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

> **NCT00001040** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 300 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Saquinavir
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine

## Key facts

- **NCT ID:** NCT00001040
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 1994-05
- **Final completion:** —
- **Target enrollment:** 300 (—)
- **Last updated:** 2011-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001040, "Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00001040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*